Meeting Overview - The seventh meeting of the fifth Supervisory Board of the company was held on April 1, 2025, with all procedures complying with relevant laws and regulations [1][2] - The meeting was chaired by Mr. Zhao Enlong, with three supervisors present [1] Resolutions Passed - The Supervisory Board approved the establishment of a Market Value Management System to enhance the company's market value management practices and protect the rights of investors [2] - The company plans to apply for a comprehensive credit limit of up to RMB 1.5 billion from banks to supplement working capital, with the authorization for management to handle specific financing matters [3] - The company intends to use idle funds for entrusted wealth management and securities investment, with a total limit of up to RMB 2.5 billion, including RMB 1.9 billion for entrusted wealth management and RMB 600 million for securities investment [4]
辰欣药业: 辰欣药业股份有限公司第五届监事会第七次会议决议公告